Valuation : Imunon, Inc.

Market Cap 8.87M 7.62M 7.17M 6.55M 12.24M 838M 12.28M 85.03M 32.87M 429M 33.3M 32.57M 1.37B P/E 2026 *
-0.66x
P/E 2027 * -0.85x
Enterprise Value 8.87M 7.62M 7.17M 6.55M 12.24M 838M 12.28M 85.03M 32.87M 429M 33.3M 32.57M 1.37B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.86%
Yield 2026 *
-
Yield 2027 * -
1 day+1.28%
1 week-1.25%
Current month-3.07%
3 months-23.30%
6 months-51.23%
Current year-58.53%
1 week 1.51
Extreme 1.5066
1.64
1 month 1.51
Extreme 1.5066
1.7
Current year 1.47
Extreme 1.47
4.2
1 year 1.47
Extreme 1.47
6.02
3 years 1.47
Extreme 1.47
47.61
5 years 1.47
Extreme 1.47
219.13
10 years 1.47
Extreme 1.47
3,780.03
Manager TitleAgeSince
Chief Executive Officer 56 13/05/2024
Director of Finance/CFO 53 01/07/2026
Chief Tech/Sci/R&D Officer 73 18/02/2025
Director TitleAgeSince
Chairman 75 07/10/2014
Director/Board Member 75 08/07/2011
Director/Board Member 76 15/12/2015
Date Insider Type Main position Quantity % Market Cap. Importance
8/31/26 A Sell

General Counsel

-2,525 0.1002%
8/28/26 A Free

Chairman

7,371 0.2924%
8/28/26 A Free

Chief Technology Officer

3,626 0.1438%
Change 5-day change 1-year change 3-year change Capi.($)
+1.28%-1.25%-72.55%-90.07% 8.87M
-0.38%-2.64%+42.69%+99.03% 67.98B
-2.71%-0.71%+34.08%+81.43% 64.94B
-0.31%+6.54%-12.96%+377.83% 27.58B
+0.86%+1.65%-7.74%-13.58% 26.06B
-1.42%-4.28%+31.24%+13.27% 25.74B
-1.11%+0.90%+23.12%-18.50% 20.09B
+1.15%-14.24%+219.82%+381.14% 17.16B
+0.20%-4.68%-6.41%+560.92% 14.92B
-0.20%+8.37%+55.78%+165.57% 14.62B
Average -0.26%+0.82%+30.71%+155.70% 27.91B
Weighted average by Cap. -0.81%+0.59%+36.96%+141.11%

Financials

2026 *2027 *
Net sales - -
Net income -14.47M -12.44M -11.7M -10.68M -19.98M -1.37B -20.04M -139M -53.63M -701M -54.33M -53.14M -2.23B -19.34M -16.64M -15.65M -14.28M -26.71M -1.83B -26.8M -186M -71.71M -937M -72.65M -71.06M -2.98B
Net Debt - -
Logo Imunon, Inc.
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
20
Date Price Change Volume
04/09/26 $1.580 +1.28% 34,012
03/09/26 $1.560 0.00% 19,174
02/09/26 $1.560 -2.50% 34,222
01/09/26 $1.600 -1.84% 33,859
31/08/26 $1.630 +1.87% 18,399
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.580USD
Average target price
17.00USD
Spread / Average Target
+975.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMNN Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!